GEA
MDGL icon

Glen Eagle Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Glen Eagle Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14
Closed -$228 – 647
2017
Q2 		$228 Hold
14
– – ﹤0.01% 577
2017
Q1 		$216 Hold
14
– – ﹤0.01% 542
2016
Q4 		$209 Buy
+14
New +$225 ﹤0.01% 534

Other funds holding MDGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Glen Eagle Advisors's MDGL Position: Q3 2017 in Review

Glen Eagle Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2017, closing a stake of 14 shares — an estimated $228 sold.

Glen Eagle Advisors first reported a position in MDGL in Q4 2016 and held it in 3 quarters. The position peaked at $228 in Q2 2017. 53 funds tracked by Wall St. Rank hold MDGL as of Q3 2017.

  • Glen Eagle Advisors reported no remaining Madrigal Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Glen Eagle Advisors sold 14 Madrigal Pharmaceuticals shares in Q3 2017, an estimated $228.
  • Glen Eagle Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Glen Eagle Advisors's Madrigal Pharmaceuticals position peaked at $228 in Q2 2017.
  • 53 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2017.

Based on Glen Eagle Advisors's 13F filing for Q3 2017, filed 13 Aug 2024.